6099.T
The company operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, generating revenue primarily through its operations in this field.
Business. 6099.T is a biotechnology company operating within the Healthcare Facilities & Services industry. The firm generates revenue through service-based models typical of healthcare facilities and services providers. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6099.T is a biotechnology company operating within the Healthcare Facilities & Services industry. The firm generates revenue through service-based models typical of healthcare facilities and services providers. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
The company maintains a strong liquidity position, with a current ratio of 1.68 and a significant cash and equivalents balance of 6,845,410,000 JPY. The price-to-book ratio of 2.92 and a low debt-to-equity ratio of 0.06 indicate a conservative capital structure. The company's return on equity of 19.16% and return on assets of 10.53% suggest strong profitability relative to its equity and asset base.
The company's operating income of 4,269,245,000 JPY and net income of 2,767,761,000 JPY reflect solid performance in the healthcare services and equipment industry. The company's gross profit of 11,874,220,000 JPY and operating margin of 7.7% are in line with industry expectations. The company's price-to-earnings ratio of 15.23 and enterprise value to EBITDA of 8.47 indicate a reasonable valuation relative to earnings and cash flow.
The company's revenue is concentrated in a single segment, with no disclosed geographic diversification. This concentration may pose a risk if the segment experiences a downturn or if regulatory changes impact the healthcare services and equipment industry. The company's revenue of 55,448,687,000 JPY is derived from its operations in this segment.
The company's growth trajectory is positive, with a mean revenue estimate of 60,500,000,000 JPY for the upcoming fiscal year. The company's free cash flow of 2,235,101,000 JPY and operating cash flow of 4,304,338,000 JPY support its ability to fund operations and invest in growth. The company's capital expenditure of -1,156,390,000 JPY indicates a reduction in capital spending.
The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash position reduce the likelihood of dilution in the near term. The company's conservative capital structure and strong liquidity position support its ability to manage financial risks.
Recent events and filings indicate that the company's performance is in line with analyst estimates. The company's last actual EPS of 45.77 JPY is below the mean estimate of 52.90 JPY, suggesting potential for improvement in earnings performance. The company's last actual revenue of 55,448,690,000 JPY is below the mean estimate of 60,500,000,000 JPY, indicating potential for revenue growth.
- The company has a strong liquidity position with a current ratio of 1.68 and significant cash reserves.
- The company's return on equity of 19.16% and return on assets of 10.53% indicate strong profitability.
- The company's revenue is concentrated in a single segment, which may pose a risk if the segment experiences a downturn.
- The company's growth trajectory is positive, with a mean revenue estimate of 60,500,000,000 JPY for the upcoming fiscal year.
- The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected.
- The company's performance is in line with analyst estimates, with potential for improvement in earnings and revenue.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 52,90 |
| Revenue | —no estimate | —no estimate | 60,5B JPY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 6099.T Market data — financials · 2026-05-27
- Elan Corp Market data — analyst estimates · 2026-05-27